Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Lenalidomide + Rituximab & Follicular Lymphoma (FL)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Lenalidomide + Rituximab (R²) is approved by the FDA and EMA for adult patients with relapsed/refractory Follicular Lymphoma (FL) and marginal zone lymphoma.

The approval was primarily based on the AUGMENT study (NCT01938001) and supported by the MAGNIFY study (NCT01996865) (1, 2)

(1) [u-s-food-and-drug-administration-approves-chemo-free-therapy-for-relapsedrefractory-indolent-lymphomas](https://lymphoma.org/news/u-s-food-and-drug-administrati…

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Morschhauser et al. 2018 NEJM 379: 934 -947

7/1/2026